Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis (NCT03575156) | Clinical Trial Compass
CompletedNot Applicable
Microparticles's Role in the Pathophysiology of Systemic Lupus Erythematosus and Systemic Sclerosis
France208 participantsStarted 2018-09-20
Plain-language summary
Our study aims at defining the role of circulating microparticles in the physiopathology of two rare auto-immune diseases: systemic lupus erythematosus (SLE) and systemic scleroderma (SSc). Microparticles might have an prognostic and diagnostic interest as well as potential for the discovery of new therapeutic strategies.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* diagnosis of systemic lupus erythematosus or systemic sclerosis;
* age ≥ 18 years;
* being affiliated to health insurance, willing to participate and to sign informed consent.
Exclusion Criteria:
* pregnant or breastfeeding women;
* patient concerned by articles L 1121-5 to L 1121-8 (persons deprived of their liberty by a judicial or administrative decision, minors, persons of legal age who are the object of a legal protection measure or unable to express their consent)
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial was studying microparticles in the blood and urine of people with lupus or scleroderma over 12 months — since it's now completed, has any data been published yet, and what did it find about how microparticle levels change over time in people with my condition?
2Since this was an observational study measuring microparticle levels rather than testing a treatment, what would participating or having participated in something like this actually mean for my care — would it change any treatment decisions, or is it purely contributing to research?
3The trial tracked both blood and urine samples at baseline and again at 12 months — if I were to take part in a similar future study, how would that schedule of visits and sample collections fit with my existing monitoring appointments for lupus or scleroderma?
4Since this study was observational and not a treatment trial, would my doctor recommend I also look into trials that are actually testing therapies for my condition, given that this one wouldn't directly offer a treatment benefit?
5Now that this trial is completed, is my doctor aware of any follow-up studies building on what was learned about microparticles in lupus or scleroderma that might be worth discussing as a next step?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Change in quantitative levels of circulating MPs between baseline and 12 months in the blood and urine samples of SLE and SSc patients
Timeframe: At baseline (Day 0) and 12 months from baseline